Drug intelligence / Profile preview

EL-MT

Development stage: Unknown
Lead developer: Northstrive Biosciences
Modality: Small Molecules

Overview

EL-MT is a discovery-stage drug discovery program developed by Northstrive Biosciences in collaboration with YocoBio. The program utilizes an AI-driven platform to identify and develop small-molecule modulators of mitochondrial targets. It is positioned within Northstrive's therapeutic focus on muscle loss and aesthetics. The platform aims to leverage artificial intelligence to accelerate the identification of novel compounds that can influence mitochondrial function, which is critical for cellular energy production and muscle health.

Other names: EL-MT Mitochondrial Drug Discovery (AI Platform)EL-MT Mitochondrial Drug Discovery

Beyond the preview

Go deeper on EL-MT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EL-MT.

Explore the full profile